For decades, healthcare has largely been built around responding to illness after it develops. Blood pressure rises, cholesterol levels increase, symptoms emerge, and medical intervention follows. While this approach has significantly improved life expectancy, it has also highlighted an important limitation: many of the biological changes that contribute to chronic disease begin years, or even decades, before they can be detected through conventional testing.
As healthcare increasingly shifts toward prevention, researchers and technology companies are asking a different question. Rather than waiting for disease to appear, can we measure the subtle biological changes that occur much earlier?
John Mulder, CEO of Diagnoptics Technologies, believes the answer lies in making previously invisible processes measurable.
“We’ve become very good at tracking what happens after health begins to decline,” Mulder says. “The next step is understanding what’s happening long before people become ill.”
This shift reflects a broader evolution in how health is being measured.
Consumer technology has transformed public awareness of personal health data. Millions of people now monitor daily step counts, heart rate, sleep quality, blood oxygen, and exercise performance through wearable devices. These metrics have encouraged greater engagement with health and wellness, but they primarily measure external behaviours or short-term physiological changes.
Increasingly, attention is turning toward biological processes that operate beneath the surface.
One of these is glycation, a naturally occurring process in which sugars bind to proteins, fats, and DNA within the body. Over time, these reactions produce compounds known as Advanced Glycation End Products, or AGEs.
AGEs accumulate gradually throughout life and are influenced by factors such as ageing, diet, blood sugar regulation, smoking, physical activity, and overall metabolic health.
While glycation itself is a normal biological process, excessive accumulation has been associated with tissue stiffness, reduced cellular function, and a variety of age-related conditions.
Unlike many traditional health indicators, however, AGEs cannot be detected simply by observing how someone feels.
“The challenge is that this damage develops quietly,” Mulder explains. “By the time symptoms appear, many of the underlying biological changes have already been taking place for years.”
This presents an important opportunity for preventive healthcare.
Rather than measuring disease itself, technologies capable of assessing tissue health may provide insight into long-term biological ageing before clinical problems become apparent.
Diagnoptics has focused its work on developing non-invasive technology capable of measuring AGE accumulation within human tissue.
Using optical measurement techniques, the technology analyses fluorescence emitted naturally by accumulated AGEs, providing healthcare professionals with an indication of tissue health without requiring invasive procedures.
The concept reflects a broader trend occurring throughout modern medicine.
Healthcare is increasingly moving beyond isolated laboratory values toward integrated biological measurements that provide a more complete picture of long-term health.
Rather than asking whether someone currently has a disease, clinicians are becoming increasingly interested in understanding how healthy the body’s tissues remain over time.
This distinction is particularly relevant as populations continue to age.
Longer life expectancy has created growing interest not only in lifespan but also in healthspan, the number of years people remain healthy, active, and independent.
Maintaining tissue health, metabolic function, and physiological resilience has therefore become an important focus within preventive medicine.
Technology is playing an increasingly significant role in supporting this transition.
Advances in imaging, artificial intelligence, digital health platforms, and non-invasive diagnostics are allowing clinicians to collect information that was previously difficult or impossible to measure outside research settings.
These innovations are gradually expanding the range of health indicators available to both medical professionals and individuals.
For Mulder, one of the most valuable aspects of objective measurement is its ability to influence behaviour.
Many lifestyle recommendations, such as improving nutrition, increasing physical activity, or managing blood sugar, offer benefits that accumulate gradually over many years. Because those benefits are often invisible in the short term, maintaining motivation can be challenging.
When people are able to visualise biological changes occurring inside their own bodies, health advice can become more immediate and personally meaningful.
“Seeing measurable changes often creates a different kind of conversation,” Mulder says. “People become more engaged because the information relates directly to their own health rather than general recommendations.”
This behavioural dimension is becoming increasingly important across preventive healthcare.
Evidence consistently shows that sustained lifestyle improvements depend not only on education but also on personal engagement and ongoing feedback.
Objective measurements can therefore serve as both diagnostic tools and motivational instruments.
Looking ahead, the future of health technology is likely to involve a broader range of biomarkers that move beyond traditional clinical testing.
Rather than focusing exclusively on disease diagnosis, emerging technologies aim to measure resilience, biological ageing, tissue quality, and long-term physiological health before significant decline occurs.
This evolution aligns with a larger transformation taking place throughout healthcare.
Medical systems around the world are gradually shifting from reactive models centred on treatment toward preventive models focused on maintaining health over time.
Success will increasingly depend on identifying meaningful biological changes early enough to influence outcomes through lifestyle, clinical intervention, and personalised care.
Within this landscape, technologies that make invisible biological processes visible may become an important part of everyday healthcare.
For Mulder, that represents the real promise of innovation.
“The future of healthcare isn’t simply about treating disease more effectively,” he says. “It’s about giving people the information they need to protect their health before disease has the opportunity to take hold.”
As prevention continues to shape the next generation of medicine, measuring what was once invisible may become one of the most valuable tools available for extending not only how long people live, but how well they live throughout those years.
